Stifel Nicolaus Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price

Becton, Dickinson and Company (NYSE:BDX) had its price objective reduced by Stifel Nicolaus from $224.00 to $210.00 in a research note issued on Friday,MarketScreener reports. Stifel Nicolaus’ price target would indicate a potential upside of 18.06% from the company’s current price.

A number of other research analysts also recently weighed in on the stock. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Argus increased their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Piper Sandler cut their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Royal Bank Of Canada cut their price target on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research note on Friday. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Stock Up 0.3%

Shares of Becton, Dickinson and Company stock opened at $177.88 on Friday. The company has a market capitalization of $50.99 billion, a P/E ratio of 31.99, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The business has a 50-day moving average of $186.77 and a two-hundred day moving average of $182.42. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. As a group, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 1,249 shares of company stock worth $231,358 in the last ninety days. 0.36% of the stock is owned by company insiders.

Institutional Trading of Becton, Dickinson and Company

Institutional investors have recently bought and sold shares of the business. Saudi Central Bank bought a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $26,000. Activest Wealth Management raised its holdings in Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares in the last quarter. SOA Wealth Advisors LLC. lifted its position in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 95 shares during the period. Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $31,000. Finally, Bell Investment Advisors Inc increased its position in shares of Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the period. Institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.